State boards and FDA inspectors scrutinize segregated compounding areas (SCAs), the unclassified spaces many pharmacies use to compound sterile preparations without building a full cleanroom suite. Under USP General Chapter 797, an SCA may support only Category 1 CSPs, the shortest-dated preparations the chapter recognizes, and a facility that stretches that limit or lets the area's physical conditions drift draws a citation. The same logic extends to containment segregated compounding areas for hazardous drugs under USP 800.
What a Segregated Compounding Area Covers Under USP 797
USP defines the SCA as an unclassified space with a defined perimeter that holds a primary engineering control and is suitable for preparing only Category 1 CSPs. USP permits an SCA without walls or a door, as long as the perimeter is defined and the primary engineering control inside it is an ISO Class 5 device. Pharmacies compounding under 503A/503B authority use the SCA to avoid a full cleanroom suite for lower-risk preparations, but nothing beyond Category 1 compounding may happen inside that perimeter.
Placement, Certification, and Garbing Inspectors Check
The sink serving an SCA may sit inside the defined perimeter, but it must stay at least one meter from the primary engineering control so splashes cannot reach the workspace. USP sets no specific temperature or humidity requirement for the SCA itself, though drugs or supplies stored there can trigger separate USP, FDA, or manufacturer storage rules. Before an SCA compounds Category 1 CSPs at all, it must be independently certified against the chapter's requirements and, where applicable, the device manufacturer's specifications; a lapsed certification means the area no longer meets that requirement. Cleanroom Certification and Recertification Timelines and Environmental Monitoring Programs Under Inspection cover the certification schedule and the separate air and surface sampling obligations. Garbing inside an SCA follows the same minimum standard as a cleanroom suite, sterile gloves for anything handled inside the primary engineering control, with hand hygiene and garbing order set by the facility's own written procedures. State boards enforce these conditions differently, so confirm your own board's reading before relying on this summary.
Containment Segregated Compounding Areas Under USP 800
USP 800 carries the same structure forward for hazardous drugs through the containment segregated compounding area, but only Category 1 hazardous-drug CSPs, sterile-to-sterile or nonsterile-to-sterile, may be prepared there. Water sources and drains must sit at least one meter from the containment primary engineering control, and hazardous drugs awaiting nonsterile compounding should not share storage with sterile-compounding inventory, to limit traffic into the sterile area. Fixed walls, not temporary partitions, are required wherever a containment segregated compounding area or an HD buffer room separates hazardous compounding from the rest of the facility. USP 800 Hazardous Drug Compliance for Pharmacies covers the fuller set of storage, ventilation, and personal protective equipment obligations.
Citation Patterns Inspectors Use
Four patterns recur in SCA deficiency findings. Inspectors cite a Category 2 CSP, which requires a longer beyond-use date that only a cleanroom suite can support, when it is labeled or dated as though it came from an SCA. Beyond-Use Dating: Where Compounders Get Cited and Extending Beyond-Use Dates: What Justifies It cover how a beyond-use date is set and challenged. They also cite an SCA compounding without a current certification on file. A physical condition, sink distance, perimeter definition, or primary engineering control placement that does not match the certification or the facility's own procedures draws the same result. So does a compounding record whose assigned BUD and storage requirements, a required entry under the chapter, point to a category the certified area was not certified to produce.
A segregated compounding area certified for Category 1 preparations only becomes a citation the moment a Category 2 beyond-use date, a lapsed certification, or a record assigning a BUD the area was not certified to produce turns up in the file.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a state board inspection report, an FDA Form 483, or any other citation naming a segregated compounding area deficiency. Early legal intervention can protect the pharmacy's rights, shape the corrective action record before a single finding becomes a pattern, avoid inadvertent admissions in the response, and allow counsel to communicate with the board or the agency on the pharmacy's behalf. Delaying representation can turn a correctable physical finding into a license or registration proceeding.
How Health Law Alliance Can Help
Health Law Alliance has handled 5,000+ matters over 25+ years. If your pharmacy has received a citation or deficiency finding tied to a segregated compounding area or its certification, contact Health Law Alliance's compounding pharmacy attorneys for a free, confidential consultation before you submit a corrective action plan.
